Lara D. Veeken · 2019 · 32 citations · 19 references
Public HealthMaternal HealthObstetricsGestational DiabetesMaternal-fetal MedicineObstetric ComplicationsFetal OutcomesIntrauterine Growth RestrictionMaternal ComplicationsMaternal Medical Complications In PregnancyMaternal MorbidityPregnancyAutoimmune Pregnancy ComplicationsConnective Tissue Disease PathologyIntrauterine Fetal Growth RestrictionLive Birth Outcome AssessmentMiscarriage EpidemiologyPregnancy MorbidityPregnancy Outcome CriteriaPregnancy-related Complications
OBJECTIVES: To investigate fetal/perinatal and maternal outcomes from a large multicentre cohort of women diagnosed with UCTD. METHODS: This multicentre retrospective cohort study describes the outcomes of 224 pregnancies in 133 consecutive women with a diagnosis of UCTD, positive for ANA and aged <45 years old at study inclusion. RESULTS: Of the 224 pregnancies analysed, 177 (79%) resulted in live births, 45 (20.1%) in miscarriages (defined as pregnancy loss before 12 weeks' gestation), 2 (0.9%) in stillbirths (pregnancy loss after 20 weeks' gestation) and 6 (2.7%) cases showed intrauterine growth restriction. Miscarriages and stillbirths were strongly associated with the presence of aPL and ENA antibodies (P < 0.05). Maternal pregnancy complications were as follows: 5 (2.2%) cases developed pre-eclampsia, 11 (4.9%) cases gestational hypertension and 12 (5.4%) cases gestational diabetes. Joint involvement represented the most frequent clinical manifestation of the cohort (57.9%), followed by RP (40.6%), photosensitivity (32.3%) and haematological manifestations (27.1%). The rate of disease evolution of our cohort from a diagnosis of UCTD to a diagnosis of definite CTD was 12% within a mean time of 5.3 ± 2.8 years. With a total follow-up after first pregnancy of 1417 patient-years, we observed the evolution to a defined CTD in one out of every 88 patient- years. CONCLUSION: In our multicentre cohort, women with UCTD had a live birth rate of 79%. Women with UCTD should be referred to specialist follow-up when planning a pregnancy. ENA profiling and aPL testing should be mandatory in this setting, and further therapeutic approaches and management should be planned accordingly.
19
General Cardiovascular Risk Profile for Use in Primary Care
Ralph B. D’Agostino, Ramachandran S. Vasan, Michael Pencina et al. · Circulation · 2008 · 7.5K citations · Full text
Medicine, Cardiology, Risk Analysis +16
Maternal age and fetal loss: population based register linkage study
Anne‐Marie Nybo Andersen · BMJ · 2000 · 1.7K citations · Full text
Peter Izmirly, N. Costedoat‐Chalumeau, Cecilia Pisoni et al. · Circulation · 2012 · 452 citations · Full text